LAVA Therapeutics BV (LVTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LVTX Stock Summary
- LVTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.53 -- higher than only 4.94% of US-listed equities with positive expected earnings growth.
- LAVA THERAPEUTICS NV's stock had its IPO on March 25, 2021, making it an older stock than merely 6.4% of US equities in our set.
- Revenue growth over the past 12 months for LAVA THERAPEUTICS NV comes in at 233.3%, a number that bests 96.3% of the US stocks we're tracking.
- Stocks that are quantitatively similar to LVTX, based on their financial statements, market capitalization, and price volatility, are HOWL, EIGR, SQZ, IKNA, and INO.
- To dig deeper into the stock's financial statements, go to LVTX's page on browse-edgar?action=getcompany&CIK=0001840748.
LVTX Stock Price Chart Interactive Chart >
LVTX Price/Volume Stats
|Current price||$5.83||52-week high||$7.89|
|Prev. close||$5.89||52-week low||$2.28|
|Day high||$5.98||Avg. volume||236,467|
|50-day MA||$4.36||Dividend yield||N/A|
|200-day MA||$3.64||Market Cap||147.80M|
LAVA Therapeutics BV (LVTX) Company Bio
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates
Most Popular Stories View All
LVTX Latest News Stream
|Loading, please wait...|
LVTX Latest Social Stream
View Full LVTX Social Stream
Latest LVTX News From Around the Web
Below are the latest news stories about LAVA THERAPEUTICS NV that investors may wish to consider to help them evaluate LVTX as an investment opportunity.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vyant Bio (VYNT – Research Report), Cybin (CYBN – Research Report) and LAVA Therapeutics (LVTX – Research Report) with bullish sentiments. Vyant Bio (VYNT) H.C. Wainwright analyst Edward White maintained a Buy rating on Vyant Bio today and set a price target of $13.00. The company's shares closed last Wednesday at $1.36, close to its 52-week low of $1.35. According to TipRanks.
LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclin
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RAPT Therapeutics (RAPT – Research Report), Vaccitech Plc (VACC – Research Report) and LAVA Therapeutics (LVTX – Research Report) with bullish sentiments. RAPT Therapeutics (RAPT) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on RAPT Therapeutics today and set a price target of $50.00. The company's shares closed last Friday at $24.17. According to TipRanks.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the Jefferies London Healthcare Conference. Presentation DetailsFormat: Fireside Chat Date: T
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated data including safety, pharmacodynamics and pharmacokinetics from the ongoing Phase 1/2a clinical trial of LAVA-051 during the 64th American Society of Hema
LVTX Price Returns